deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT03063203

Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia

An Open Label, Multicenter, Phase II Trial Testing Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia

Sponsor: Janssen Pharmaceuticals

Conditions Acute Myeloid Leukemia Acute Myeloid Leukemia, Relapsed, Adult
Interventions Bone marrow biopsy/aspirate Buccal swab Decitabine Peripheral blood draw Skin biopsy
Updated 17 times since 2017 Last updated: May 9, 2022 Started: Jul 14, 2017 Primary completion: Feb 13, 2021 Completion: Mar 16, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Futility

Other terminated trials from Janssen Pharmaceuticals

See all terminations from Janssen Pharmaceuticals

Other Acute Myeloid Leukemia trials with similar outcome

Browse all Acute Myeloid Leukemia trials

Listed as NCT03063203, this PHASE2 trial focuses on Acute Myeloid Leukemia and Acute Myeloid Leukemia, Relapsed, Adult and remains terminated or withdrawn. Sponsored by Janssen Pharmaceuticals, it has been updated 17 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Apr 2017 – ~Aug 2017 · 4 months · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Feb 2019 · 7 months · monthly snapshot~Feb 2019 – ~May 2019 · 3 months · monthly snapshot~May 2019 – ~Apr 2020 · 11 months · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~Jul 2024 · 24 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jul 2022 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  5. Apr 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE2

▶ Show 12 earlier versions

  1. Sep 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Apr 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Mar 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  5. Jun 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  6. Apr 2020 — Jun 2020 [monthly]

    Recruiting PHASE2

  7. May 2019 — Apr 2020 [monthly]

    Recruiting PHASE2

  8. Feb 2019 — May 2019 [monthly]

    Recruiting PHASE2

  9. Jul 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  10. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  11. Aug 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. Apr 2017 — Aug 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Pharmaceuticals
  • National Cancer Institute (NCI)
  • National Institutes of Health (NIH)
  • Washington University School of Medicine
Data source: Washington University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations